Skip to Content
Søg Menu

Nordic AML Insights - December Update

/ Amanda Feldballe Bernholm / Jan Andreasen
AML

Sustained Survival Benefit of Cemiplimab Plus Chemotherapy at 5 Years in Advanced NSCLC With PD-L1 ≥1%

/ Jan Andreasen
LungecancerImmunterapi

Kombination af enfortumab vedotin og pembrolizumab har forbedret behandlingen af blærecancer radikalt

/ Jakob Lauritsen / Jan Andreasen
Blærecancer

Low-dose Decitabine/Cedazuridine Reduces Toxicity While Preserving Efficacy in Low-risk MDS

/ Jan Andreasen
ASH25

BPd Preserved or Improved Quality of Life in Patients with RRMM

/ Paul G. Richardson / Jan Andreasen
ASH25Myelomatose

Lung Cancer Insights: What’s New in the Field – December Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

Danish and Nordic Lung Cancer Insights – December Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

Top Abstract Spotlight: Menin Inhibitors are a Game Changer for the Treatment of Patients with Newly Diagnosed AML 

/ Jan Andreasen
ASH25AML

Fixed-Duration Venetoclax Regimens Match Continuous BTKi in Frontline CLL

/ Jan Andreasen
ASH25CLL

Beskyttet: Norwegian dermatologists' experience in treating moderate-to-severe plaque psoriasis with brodalumab in relation to clinical trials

/ LEO Pharma / Tore Morken / Evelina Buinauskaite / Ernst Veer / Thrasyvoulos Tzellos
Back to top